InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,509.01
(
0.62%
)
US TECH 100
19,460.00
(
0.95%
)
Dow Jones
39,331.85
(
0.41%
)
Brent Oil
86.51
(
0.08%
)
Bitcoin
60,855.25
(
-1.89%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 370

Sunday, 10/14/2018 12:33:53 AM

Sunday, October 14, 2018 12:33:53 AM

Post# of 438
CFRX is working to bring the first phage-derived biologic to market

CF-301 is recombinant lysin that was derived from bacteriophage to combat MRSA


CF-301 can work within biofilm



Its Ph2 trial is not a non-inferiority trial. It's designed to be a proof of concept.

If the Ph2 POC trial is successful, substantially more capital will be required to conduct a Ph3 trial. I will wait until this this financing to get involved.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up